Fact-check: Stanford Health Care's dietitian webinar on managing GI side effects

What the video covers

Elaine Han, a senior dietitian and diabetes educator at Stanford Health Care, gives an hour-long webinar for patients. She explains GLP-1 physiology briefly, then presents tables pooled from about 30 clinical trials: the rare serious events (pancreatitis, gallbladder disease, at 0 to 2 percent), then the common GI effects with their ranges by program, the week-by-week course of nausea, and the practical strategies: small frequent meals, not skipping meals, less fat and fried food, cooler and less aromatic foods, more protein, liquid meals on bad days, fluids and fibre for constipation.

What it gets right

The headline figures are consistent with the primary trials. Nausea at "about 25 percent at week four, 15 percent at week eight and 5.5 percent by week 56" describes the semaglutide 1 mg time course in the SUSTAIN program. The dose-dependence comparison is the most instructive slide: nausea ranged 14 to 58 percent across STEP trials at 2.4 mg against 15 to 24 percent across SUSTAIN at 1 mg, and 3 mg liraglutide (SCALE) against 1.8 mg (LEAD) shows the same pattern. The Wegovy label's pooled figure, 44 percent nausea against 16 percent on placebo, sits inside the STEP range. Her statement that mild to moderate symptoms are not a reason to stop, and that they usually resolve within about eight days of onset, matches the labels' description of transient, dose-related events.

The food strategies are those in the labels' patient counselling and in dietitian consensus: fat slows emptying further on a drug that already slows it, an empty stomach worsens nausea, protein is better tolerated than fat, and hydration and fibre address constipation. She is explicit that vomiting severe enough to prevent fluid intake is a reason to call, which is the dehydration warning in plain words.

What it leaves out or overstates

The percentages come from a published review that pooled trials rather than from a single source, and the slides are not visible in the transcript, so the exact citation cannot be checked from the video. The ranges are wide for that reason. Individual trials are more useful for a specific drug and dose: in STEP 1, 44 percent of the semaglutide 2.4 mg group reported nausea (PubMed 33567185).

Tirzepatide gets almost no attention. The Zepbound label reports nausea in 25 to 29 percent, diarrhoea in 19 to 23 percent, vomiting in 8 to 13 percent and constipation in 11 to 17 percent across the 5, 10 and 15 mg arms, with the same early clustering. A tirzepatide user can apply every strategy in the webinar, but should read the rates from that label rather than the semaglutide tables.

The protein advice ("a high-protein diet is easier to tolerate") is sound for nausea and useful for preserving lean mass, but the webinar does not give a target. Guidance from the 2025 joint advisory on nutrition during GLP-1 therapy suggests 1.2 to 1.6 grams per kilogram of body weight per day for most adults losing weight; a clinician or dietitian should individualise it.

Where to go next

Dr. Nadolsky's video earlier in this playlist covers the medication steps when food changes are not enough. For a protein target from body weight, use the calculator on Weight Loss on GLP-1s; for the label rates by dose arm, the side-effect explorers on the Semaglutide Hub and Tirzepatide Hub. FormBlends' compounded products, described at formblends.com, are not FDA approved; the label rates above are for the brand products the trials studied.